{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"131"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"205"}],"units":"Participants"}],"description":"The change in the intended prostate cancer treatment plan will be based on Medical Management Questionnaires completed prior to and after 18F-DCFPyL PET/CT imaging.","groups":[{"description":"Participants with suspected recurrence of prostate cancer and negative or equivocal findings per institutional standard of care conventional imaging were enrolled to receive a single dose of 9 mCi (333 MBq) 18F-DCFPyL injection followed by a single PET/CT scan acquired 1 to 2 hours post-dosing.","id":"OG000","title":"18F-DCFPyL Injection"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants with a Medical Management Questionnaire (MMQ) completed at pre- and post- 18F-DCFPyL PET/CT imaging.","reportingStatus":"POSTED","timeFrame":"Pre 18F-DCFPyL PET/CT imaging and within 60 days following 18F-DCFPyL PET/CT imaging.","title":"Percentage of Participants With a Change in Intended Prostate Cancer Treatment Plans Due to 18F-DCFPyL PET/CT Imaging Results.","type":"SECONDARY","unitOfMeasure":"Participants"}